دورية أكاديمية
Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia
| العنوان: | Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia |
|---|---|
| المؤلفون: | Peñalver, Francisco Javier, Alvarez-Larrán, Alberto, Díez-Martin, Jose Luis, Gallur, Laura, Jarque, Isidro, Caballero, Dolores, Díaz-Mediavilla, Joaquín, Bustelos, Rosalía, Fernández-Aceñero, María Jesús, Cabrera, José Rafael |
| المساهمون: | Hospital Universitario Fundación Alcorcón, Hospital Clinic, Hospital Gregorio Marañon, Hospital Gregorio Marañón, Vall d'Hebron University Hospital Barcelona, Hospital La Fe, Hospital Clínico de Salamanca, Hospital Clínico de Madrid, Hospital Universitario 12 de Octubre, Hospital Universitario 12 de Octubre Madrid, Fundación Jiménez Díaz, Biostatistics, Hospital Universitario Puerta de Hierro |
| المصدر: | ISSN: 0939-5555. |
| بيانات النشر: | HAL CCSD Springer Verlag |
| سنة النشر: | 2010 |
| المجموعة: | Archive ouverte HAL (Hyper Article en Ligne, CCSD - Centre pour la Communication Scientifique Directe) |
| مصطلحات موضوعية: | Rituximab, Autoimmune hemolytic anemia, Refractory |
| الوصف: | International audience ; Rituximab-induced B-cell depletion has been proven to be a useful therapy for autoimmune hemolytic anemia (AIHA). The aim of this retrospective study was to evaluate the effectiveness of rituximab in the treatment of 36 patients with AIHA refractory to several treatments. These patients had received a median of four (one to eight) previous treatments, and 13 patients had undergone splenectomy. Rituximab was administered by intravenous infusion at a dose of 375 mg/m once weekly for four doses in 29 patients, and 7 patients received one to six doses. Overall, 28 (77%) of 36 patients achieved response. Twenty-two patients (61%) reached a complete response (CR), and 6 patients (16%) obtained a partial response. All patients that reached CR (61%) were able to maintain the response during more than 6 months, with a median follow-up of 14 months (1–86 months). Sixteen patients maintained response for more than 1 year. The predictors of maintained response were achievement of CR and negative Coombs test result. Splenectomized patients showed a better response rate than those nonsplenectomized. Rituximab was well tolerated, and only one patient presented a transitory rash during infusion. Rituximab induced clinical responses in multitreated severe refractory both warm and cold AIHA patients with little toxicity, and consequently, this therapy should be considered as an early therapeutic option in this setting. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | hal-00543002; https://hal.archives-ouvertes.fr/hal-00543002Test; https://hal.archives-ouvertes.fr/hal-00543002/documentTest; https://hal.archives-ouvertes.fr/hal-00543002/file/PEER_stage2_10.1007%252Fs00277-010-0997-y.pdfTest |
| DOI: | 10.1007/s00277-010-0997-y |
| الإتاحة: | https://doi.org/10.1007/s00277-010-0997-yTest https://hal.archives-ouvertes.fr/hal-00543002Test https://hal.archives-ouvertes.fr/hal-00543002/documentTest https://hal.archives-ouvertes.fr/hal-00543002/file/PEER_stage2_10.1007%252Fs00277-010-0997-y.pdfTest |
| حقوق: | info:eu-repo/semantics/OpenAccess |
| رقم الانضمام: | edsbas.14938F66 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1007/s00277-010-0997-y |
|---|